{
  "id": 18571505,
  "title": "Zenas BioPharma launches new $200 million at-the-market stock offering",
  "url": "https://urgent.news/2026/11/06/zenas-biopharma-launches-new-200-million-at-the-market-stock-offering",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-06T21:24:40.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/sec-filings/zenas-biopharma-launches-new-200-million-atthemarket-stock-offering-93CH-5009199"
  },
  "original_language": "en",
  "account": "Zenas BioPharma, Inc. (NASDAQ:ZBIO) has launched a new at-the-market (ATM) stock offering program, with a potential sale of up to $200 million in common stock, according to a press release filed with the Securities and Exchange Commission. This new program, facilitated by Jefferies LLC, replaces an earlier ATM offering initiated in October 2025, which had allowed the company to sell up to $200 million of its stock. As of the latest trade, the stock was priced at $28.26, experiencing a decline of nearly 9% over the past week and a significant 29% decrease year-to-date. The company has already sold approximately $153.2 million under the prior program, leaving about $46.8 million in authorized shares unsold. The new offering is contingent upon the company's decision to proceed with sales. Legal counsel Ropes & Gray LLP has provided an opinion on the new shares covered by the prospectus supplement. The company's common stock, listed under the ticker symbol ZBIO, is traded on The Nasdaq Global Select Market and is incorporated in Delaware under the pharmaceutical preparations classification. Analysts at Morgan Stanley, H.C. Wainwright, and Guggenheim have released recent reports on Zenas BioPharma, expressing varying degrees of confidence in the potential market impact of their treatments, particularly the bifunctional antibody obexelimab, which is being tested for its efficacy in treating IgG4-related disease.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}